查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1442891

人类乳突病毒疫苗市场（适应症：子宫颈癌、肛门癌、阴道癌、阴茎癌、外阴癌、口咽癌、生殖器疣等）全球产业分析、规模、份额、成长、趋势和预测，2023-2031

Human Papillomavirus Vaccine Market (Indication: Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts, & Others) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 212 Pages | 商品交期: 2-10个工作天内

价格

人类乳突病毒疫苗市场 - 报告范围

TMR 关于全球人类乳突病毒疫苗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球人类乳突病毒疫苗的收入2017-2031年期间的市场，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球人类乳突病毒疫苗市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解人类乳突病毒疫苗市场。

该报告深入探讨了全球人类乳突病毒疫苗市场的竞争格局。全球人类乳突病毒疫苗市场的主要参与者已经确定，并对每个参与者的不同属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球人类乳突病毒疫苗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：by Valence

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按Valence，2017-2031
    • 二价
    • 四价和九价
  • 市场吸引力分析：按价

第 7 章：全球市场分析与预测：依指标分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依指标划分，2017-2031
    • 子宫颈癌
    • 肛门癌
    • 阴道癌
    • 阴茎癌
    • 外阴癌
    • 口咽癌
    • 尖圭湿疣
    • 其他的
  • 市场吸引力分析：依指标分类

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2017-2031
    • 医生
    • 批发商
    • 医师经销商
    • 政府机构
    • 公私联盟
  • 市场吸引力分析：依指标分类

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi
    • AstraZeneca
    • Serum Institute of India Pvt. Ltd.
    • Xiame Innovax Biotech Co., Ltd.
    • General Incorporated Foundation
    • The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
    • Bharat Biotechare
Product Code: TMRGL37085

Human Papillomavirus Vaccine Market - Scope of Report

TMR's report on the global human papillomavirus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global human papillomavirus vaccine market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global human papillomavirus vaccine market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the human papillomavirus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global human papillomavirus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global human papillomavirus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus vaccine market.

The report delves into the competitive landscape of the global human papillomavirus vaccine market. Key players operating in the global human papillomavirus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global human papillomavirus vaccine market profiled in this report.

Key Questions Answered in Global human papillomavirus vaccine Market Report:

  • What is the sales/revenue generated by human papillomavirus vaccine across all regions during the forecast period?
  • What are the opportunities in the global human papillomavirus vaccine market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Human Papillomavirus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global human papillomavirus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global human papillomavirus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus vaccine market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Valence, 2017-2031
    • 6.3.1. Bivalent
    • 6.3.2. Quadrivalent and Nonavalent
  • 6.4. Market Attractiveness Analysis, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2017-2031
    • 7.3.1. Cervical Cancer
    • 7.3.2. Anal Cancer
    • 7.3.3. Vaginal Cancer
    • 7.3.4. Penile Cancer
    • 7.3.5. Vulvar Cancer
    • 7.3.6. Oropharyngeal Cancer
    • 7.3.7. Genital Warts
    • 7.3.8. Others
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Physicians
    • 8.3.2. Wholesalers
    • 8.3.3. Physician Distributors
    • 8.3.4. Government Entities
    • 8.3.5. Public and Private Alliances
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Valence, 2017-2031
    • 10.3.1. Bivalent
    • 10.3.2. Quadrivalent and Nonavalent
  • 10.4. Market Value Forecast, by Indication, 2017-2031
    • 10.4.1. Cervical Cancer
    • 10.4.2. Anal Cancer
    • 10.4.3. Vaginal Cancer
    • 10.4.4. Penile Cancer
    • 10.4.5. Vulvar Cancer
    • 10.4.6. Oropharyngeal Cancer
    • 10.4.7. Genital Warts
    • 10.4.8. Others
  • 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.5.1. Physicians
    • 10.5.2. Wholesalers
    • 10.5.3. Physician Distributors
    • 10.5.4. Government Entities
    • 10.5.5. Public and Private Alliances
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Valence
    • 10.7.2. By Indication
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Valence, 2017-2031
    • 11.3.1. Bivalent
    • 11.3.2. Quadrivalent and Nonavalent
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Cervical Cancer
    • 11.4.2. Anal Cancer
    • 11.4.3. Vaginal Cancer
    • 11.4.4. Penile Cancer
    • 11.4.5. Vulvar Cancer
    • 11.4.6. Oropharyngeal Cancer
    • 11.4.7. Genital Warts
    • 11.4.8. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Physicians
    • 11.5.2. Wholesalers
    • 11.5.3. Physician Distributors
    • 11.5.4. Government Entities
    • 11.5.5. Public and Private Alliances
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Valence
    • 11.7.2. By Indication
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Valence, 2017-2031
    • 12.3.1. Bivalent
    • 12.3.2. Quadrivalent and Nonavalent
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Cervical Cancer
    • 12.4.2. Anal Cancer
    • 12.4.3. Vaginal Cancer
    • 12.4.4. Penile Cancer
    • 12.4.5. Vulvar Cancer
    • 12.4.6. Oropharyngeal Cancer
    • 12.4.7. Genital Warts
    • 12.4.8. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Physicians
    • 12.5.2. Wholesalers
    • 12.5.3. Physician Distributors
    • 12.5.4. Government Entities
    • 12.5.5. Public and Private Alliances
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Valence
    • 12.7.2. By Indication
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Valence, 2017-2031
    • 13.3.1. Bivalent
    • 13.3.2. Quadrivalent and Nonavalent
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Cervical Cancer
    • 13.4.2. Anal Cancer
    • 13.4.3. Vaginal Cancer
    • 13.4.4. Penile Cancer
    • 13.4.5. Vulvar Cancer
    • 13.4.6. Oropharyngeal Cancer
    • 13.4.7. Genital Warts
    • 13.4.8. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Physicians
    • 13.5.2. Wholesalers
    • 13.5.3. Physician Distributors
    • 13.5.4. Government Entities
    • 13.5.5. Public and Private Alliances
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Valence
    • 13.7.2. By Indication
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Valence, 2017-2031
    • 14.3.1. Bivalent
    • 14.3.2. Quadrivalent and Nonavalent
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Cervical Cancer
    • 14.4.2. Anal Cancer
    • 14.4.3. Vaginal Cancer
    • 14.4.4. Penile Cancer
    • 14.4.5. Vulvar Cancer
    • 14.4.6. Oropharyngeal Cancer
    • 14.4.7. Genital Warts
    • 14.4.8. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Physicians
    • 14.5.2. Wholesalers
    • 14.5.3. Physician Distributors
    • 14.5.4. Government Entities
    • 14.5.5. Public and Private Alliances
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Valence
    • 14.7.2. By Indication
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Merck & Co., Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. GlaxoSmithKline plc
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Sanofi
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. AstraZeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Serum Institute of India Pvt. Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Xiame Innovax Biotech Co., Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. General Incorporated Foundation
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Bharat Biotechare
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 02: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 03: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 07: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 08: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 11: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 15: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 16: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 19: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
  • Table 23: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 24: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
  • Figure 02: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Valence, 2022
  • Figure 03: Global Human Papillomavirus Vaccine Market Value Share, by Valence, 2022
  • Figure 04: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Indication, 2022
  • Figure 05: Global Human Papillomavirus Vaccine Market Value Share, by Indication, 2022
  • Figure 06: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global Human Papillomavirus Vaccine Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global Human Papillomavirus Vaccine Market Value Share, by Region, 2022
  • Figure 09: Global Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 11: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 12: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 13: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 14: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 15: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Region, 2017 and 2031
  • Figure 17: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Country, 2017 and 2031
  • Figure 21: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 22: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 23: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 24: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 25: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 26: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 30: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 31: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 32: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 33: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 34: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 35: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 39: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 40: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 41: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 42: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 43: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 44: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Latin America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 48: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 49: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 50: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 51: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 52: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 53: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
  • Figure 57: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
  • Figure 58: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
  • Figure 59: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
  • Figure 60: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
  • Figure 61: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 62: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031